Since its 1976 emergence in Africa, the Ebola virus has proven an especially lethal contagion, killing roughly 50% of the people who contract it. The 2019 FDA approval of a vaccine, combined with the subsequent development of two antibody-based drugs, marked unprecedented progress against one species of the virus. Yet the continuing threat posed by several other types of Ebola has left researchers in pursuit of additional treatments—particularly in developing regions of Africa, where limited infrastructure can impede the storage and deployment of vaccines.